Pharma and Health Business #57, Σεπτέμβριος-Οκτώβριος 2019 by ethosMEDIA

# 035

# 057

ªôé÷ áðåéìèôéëÛ÷ çéá ôè úöÜ îÞóïù÷, áðáîôÀíå íå óôïøåùíÛîå÷ õåòáðåÝå÷, íå áðïäåäåéçíÛîï Þæåìï÷ åðéâÝöóè÷, áîôéíåôöðÝúïîôá÷ ôïî ëÀõå áóõåîÜ óáî éäéáÝôåòè ðåòÝðôöóè.

ªôèî åùøÜ ëÀõå áîõòñðïù îá íèî ôïù óùíâåÝ íéá óïâáòÜ áóõÛîåéá, áðáîôÀíå íå ðòïìèðôéëÛ÷ åêåôÀóåé÷ ðïù Ûøïùî ëáôáêéñóåé ôè Roche ö÷ ðáçëÞóíéï èçÛôè ëáé óôï øñòï ôöî äéáçîöóôéëñî.

ºé Þôáî äåî Ûøïùíå áëÞíá áðáîôÜóåé÷, óùîåøÝúïùíå îá ôé÷ áîáúèôÀíå, ðÀîôá íå óåâáóíÞ, óôï ðìåùòÞ ôïù áóõåîÜ.

6 Ρεπορτάζ

Το

10 Ρεπορτάζ Ευρωπαϊκή

13 Αφιέρωμα

14 Συνέντευξη

20 Άρθρο

24 Άρθρο

28 Άρθρο

ΙQVIA:

38 Άρθρο

42 Άρθρο

46 Ρεπορτάζ

50 Ρεπορτάζ

52 Newsroom Oncology

58 Άρθρο

64 Άρθρο

66 Άρθρο

70 Newsroom

78 Ανάλυση VRS

T: 210 9984950, Φ: 210 9984953

E: info@virus.com.gr

• www.virus.com.gr • www.phb.com.gr

• www.ethosmedia.eu

• www.ethosevents.eu

• www.banks.com.gr

• www.insuranceworld.gr

ISSN: 2241-0961

EVALUATEPHARMA & GLOBALDATA

EvaluatePharma.

pembrolizumab

GlobalData.

GlobalData:

GlobalData

05.12.19

Athenaeum InterContinental

Michele Cavo*

Who is who

Η θεραπεία με CAR-T

απομονώνοντας τα Τ-λεμφοκύτταρα. Στη

συνέχεια, αυτά τα κύτταρα μεταφέρονται με ασφάλεια σε ένα εξειδικευμένο κέντρο παρασκευής, όπου τροποποιούνται σε CAR-T κύτταρα, που μπορούν να αναγνωρίσουν έναν συγκεκριμένο στόχο. Στους ασθενείς χορηγούνται χαμηλές δό-

κύκλου, ενισχύοντας την ανοσιακή α-

απάντηση

Εικόνα 1. Predicted percentage change in productivity per trend in oncology from 2018 to 2023 from the Global Oncology Trends 2019 – Therapeutics, Clinical Development and Health System Implications. IQVIA Institute for Human Data Science, May 2019 report.

Εικόνα 2. Clinical trials participation by physician’s specialty. Source: Physician’s perspective on Clinical Trials, IQVIA Greece, 2019.

Εικόνα 3. Sources of information for Clinical Trials stated by the general public. Source from General Public Market Research, IQVIA Greece, 2019.

Εικόνα 4. Total Spending on Oncology Medicines and Supportive Care and Growth US$Bn from the Global Oncology Trends 2019 – Therapeutics, Clinical Development and Health System Implications. IQVIA Institute for Human Data Science, May 2019 report.

“survivors”

Network for Care of

Late effects

www.floga.org.gr / floga@floga.org.gr / fb syllogos floga Εθνικό

09110 ΣΥΔ 22047068Ν/0203

Μητρώο 09110 ΣΥΔ 20047068Ν/0173 Πιστοποίηση

450 14/02/2018

App Store.

Hashimoto σε ποσοστό 15-30%, η κοιλιοκάκη (4-9%),

Anti

Επίλογος

(Polyglandular Autoimmune

2. G. Soltesz, C. C. Patterson, and G. Dahlquist, “Worldwidechildhoodtype1diabetesincidence— what can we learn from epidemiology?” PediatricDiabetes, vol.8, supplement6, pp.6– 14,2007.

3. EURODIAB ACE Study Group, “Variation and trends in incidence of childhood diabetes in Europe,” TheLancet, vol. 355, no. 9207, pp.873–876, 2000.

4. The DIAMOND Project Group, “Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999”, Diabetic Medicine, vol. 23, no. 8, pp. 857-866, 2006.

5. C. C. Patterson, G. G. Dahlquist, E. Gyürüs, A. Green, and G. Soltész, “Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005–20: a multicentre prospective registration study”, The Lancet, vol. 373, no. 9680, pp. 2027-2033, 2009.

6. Green and C. C. Patterson, “Trends in the incidence of childhood-onset diabetes in Europe 1989-1998,” Diabetologia, vol. 44, supplement 3, pp. B3-B8, 2001.

7. khkhk

8. J. M. Barker, “Clinical review: type 1 diabetesassociated autoimmunity: natural history, genetic associations, and screening”, Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 4, pp. 1210-1217, 2006.

9. W. E. Winter and D. A. Schatz, “Autoimmune markers in diabetes”, Clinical Chemistry, vol. 57, no. 2, pp. 168-175, 2011.

10. D. Leslie, P. Lipsky, and A. L. Notkins, “Autoantibodies as predictors of disease”, The Journal of Clinical Investigation, vol. 108, no. 10, pp. 1417-1422, 2001.

11. K. Kakleas, A. Soldatou, F. Karachaliou, and K. Karavanaki, “Associated autoimmune diseases in children and adolescents with type1 T1 DM (T1DM)”, Autoimmunity Reviews, vol. 14, no. 9, pp. 781-797, 2015.

12. M.Knipand H. Siljander, “The role of the intestinal microbiota in type 1 diabetes mellitus” Nature Reviews Endocrinology, vol. 12, no. 3, pp. 154-167, 2016

13. O. Kordonouri, A. Klinghammer, E. B. Lang, A. GrütersKieslich, M. Grabert, and R. W. Holl”, Thyroid autoimmunity in children and adolescents with type 1 diabetes: a multicenter survey,”Diabetes Care, vol. 25, no. 8, pp. 1346-1350, 2002.

14. K. Kakleas, E. Paschali, N. Kefalas et al., “Factors for thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus”, Upsala Journal of Medical Sciences, vol. 114, no. 4, pp. 214-220, 2009.

15. O. Kordonouri, R. Hartmann, D. Deiss, M. Wilms, and A. Grüters-Kieslich,“Natural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration, and puberty”, Archives of Disease in Childhood, vol. 90, no. 4, pp. 411-414, 2005.

16. J. Peczynska, M. Urban, B. GlowinskaOlszewska, and B. Florys, “Prevalence of thyroid diseases in children and adolescents with diabetes type1”, Ped Endocrinology, vol. 5, no. 1, pp. 33-38, 2006

17. K. P. Newton and S. A. Singer, “Celiac disease in children and adolescents: special considerations”, Seminars in Immunopathology, vol. 34, no. 4, pp. 479-496, 2012.

18. G.K.T.Holmes,“Coeliac disease and type 1 diabetes mellitus-the case for screening”, Diabetic Medicine, vol. 18, no. 3, pp. 169177, 2001.

19. C. Poulain, C. Johanet, C. Delcroix, C. Lévy-

Marchal, and N. Tubiana- Rufi,“Prevalence and clinical features of celiac disease in 950 children with type 1 diabetes in France”, Diabetes and Metabolism, vol. 33, no. 6, pp. 453-458, 2007.

20. G. Barera, R. Bonfanti, M. Viscardi et al.,“Occurrence of celiac disease after onset of type 1 diabetes: a 6-year prospective longitudinal study”, Pediatrics, vol. 109, no. 5, pp. 833-838, 2002.

21. B.-H. Toh, “Diagnosis and classification of autoimmune gastritis, ”Autoimmunity Reviews, vol. 13, no. 4-5, pp. 459-462, 2014. [57] C. E. M. De Block, I. H. De Leeuw, and L. F. Van Gaal,

22. “Autoimmune gastritis in type 1 diabetes: a clinically oriented review”, Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 2, pp. 363-371, 2008.

23. K. Kakleas, M. Kostaki, E. Critselis et al., “Gastric autoimmunity in children and adolescents with type 1 diabetes: a prospective study”, Hormone Research in Paediatrics, vol. 77, no. 2, pp. 121-126, 2012.

24. C. E. M. De Block, I. H. De Leeuw, J. J. F. Vertommen et al, “Beta-cell, thyroid, gastric, adrenal and coeliac autoimmunity and HLADQ types in type 1 diabetes”, Clinical and Experimental Immunology, vol. 126, no. 2, pp. 236-241, 2001.

25. E. E. Fröhlich-Reiterer, J. Huber, H. Katz et al., “Do children and adolescents with type 1 diabetes mellitus have a higher frequency of parietal cell antibodies than healthy controls?”, Journal of Pediatric Gastroenterology and Nutrition, vol. 52, no. 5, pp. 558-562, 2011.

26. C. Jaeger, E. Hatziagelaki, R. Petzoldt, and R. G. Bretzel, “Comparative analysis of organspecific autoantibodies and celiac diseaseassociated antibodies in type 1 diabetic patients, their first-degree relatives, and

healthy control subjects”, Diabetes Care, vol. 24, no. 1, pp. 27-32, 2001.

27. G. Meyer, K. Neumann, K. Badenhoop, and R. Linder, “Increasing prevalence of addison’s disease in german females: health insurance data 2008-2012”, European Journal of Endocrinology, vol. 170, no. 3, pp. 367373, 2014.

28. C. Betterle and L. Morlin, “Autoimmune Addison’s disease”, Endocrine Development, vol. 20, pp. 161-172, 2011.

29. E. H. Kemp, N. G. Gavalas, D. J. Gawkrodger, and A. P. Weetman, “Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo”, Autoimmunity Reviews, vol. 6, no. 3, pp. 138-142, 2007.

30. E. H. Kemp, E. A. Waterman, and A. P.Weetman, “Autoimmune aspects of vitiligo”, Autoimmunity, vol. 34, no. 1, pp. 65-77, 2001.

31. A. Taïeb and M. Picardo, “The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force”, Pigment Cell Research Journal, vol. 20, no. 1, pp. 27-35, 2007.

32. K. V. Gopal, G. R. Rao, and Y. H. Kumar, “Increased prevalence of thyroid dysfunction and T1DM in Indian vitiligo patients: a casecontrol study”, Indian Dermatology Online Journal, vol. 5, no. 4, pp. 456-460, 2014.

33. G. S. Eisenbarth and P. A. Gottlieb, “Autoimmune Polyendocrine Syndromes”, The New England Journal of Medicine, vol. 350, no. 20, pp. 2068-2079, 2004.

34. C. Schneller, L. Finkel, M. Wise, J. R. Hageman, and E. Littlejohn, “Autoimmune polyendocrine syndrome: a case-based review”, Pediatric Annals, vol. 42, no. 5, pp. 203-208, 2013.

35. G. Hermann, A. Thon, K. Mönkemöller et al., “Comorbidity of type 1 diabetes and juvenile idiopathic arthritis”, Journal of Pediatrics, vol. 166, no. 4, pp. 930-935. e3, 2015.